Docetaxel is a taxane/taxoid antineoplastic agent used to treat ovarian and breast cancer. In comparison to paclitaxel, docetaxel has a higher binding affinity for tubulin, specifically the beta subunit. Docetaxel binds to tubulin dimers and enhances the polymerization of microtubules which destroys the cell's ability to use its cytoskeleton in a flexible manner. This causes the formation of discrete bundles of stable microtubules and inhibits the cellular replication of cancerous cells. It is administered as an intravenous injection. Docetaxel has dose-limiting toxic properties that cause myelosuppression, neutropenia, peripheral neurotoxicity, and mucositis. Docetaxel is metabolized by CYP3A4 so patients taking docetaxel should avoid grapefruits and other drugs that interfere with CYP3A4 metabolism.

Docetaxel Pathway (New) References